IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Mylan Laboratories Ltd. Petitioner,

v.

Janssen Pharmaceutica NV Patent Owner.

U.S. Patent No. 9,439,906 to Vermeulen et al. Issue Date: September 13, 2016
Title: Dosing Regimen Associated with Long Acting Injectable Paliperidone Esters

Inter Partes Review No.: IPR2020-00440

Declaration of Mansoor M. Amiji, Ph.D., R.Ph.

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450



Declaration of Dr. Mansoor M. Amiji

Table of Contents

1.	INTRODUCTION	l
2.	MY EXPERIENCE AND QUALIFICATIONS	2
3.	LIST OF MATERIALS CONSIDERED	9
4.	LEGAL STANDARD	14
A.	Obviousness	14
5.	PERSON OF ORDINARY SKILL IN THE ART ("POSA")	18
6.	BACKGROUND OF RELEVANT TECHNICAL CONCEPTS	20
A.	Pharmacokinetics and Drug Metabolism	20
В.	Depot Formulations and Related Pharmacokinetics and Drug Metabolism Concepts	
C.	Paliperidone and Its Use for Treatment of Patients with Schizophrenia	26
7.	THE '906 PATENT	27
8.	CLAIM CONSTRUCTION	38
9.	OBVIOUSNESS	39
A.	Ground 1: Claims 1-7, 15 and 17-21 Would Have Been Obvious over	•
	Citrome, Cleton, and the '544 Patent	40
1	The Scope and Content of the Prior Art	40
	a) The '544 Patent (EX1005)	40
	b) Cleton (EX1003)	41
	c) Citrome (EX1004)	43
2	2. The Differences Between the Claims and Prior Art	46



Declaration of Dr. Mansoor M. Amiji

	a)	Claims 1 and 4	46
	b)	Claims 2 and 15	58
	c)	Claims 3 and 5	62
	d)	Claims 6 and 7	62
	e)	Claim 17	63
	f)	Claim 18	66
	g)	Claims 19-21	67
B.	Gro	ound 2: Claims 8-14 and 16 Would Have Been Obvious Over Citrome,	
	Cle	ton, the Paliperidone Formulary and the '544 Patent	71
1.	. 7	The Scope and Content of the Prior Art	71
	a)	The '544 Patent	71
	b)	Cleton (EX1003)	71
	c)	Citrome (EX1004)	71
	d)	Paliperidone Formulary (EX1006)	71
2.	. 7	The Differences Between the Claims and Prior Art	72
	a)	Claims 8 and 11	72
	b)	Claims 9 and 16	.81
	c)	Claims 10 and 12	83
	d)	Claims 13 and 14	83
C.	Gro	ound 3: Claims 1-7, 15 and 17-21 Would Have Been Obvious over	
	Cit	come and the '544 Patent	.84
1.	. 7	The Scope and Content of the Prior Art	84
	a)	The '544 Patent (EX1005)	84



Declaration of Dr. Mansoor M. Amiji

	b) Citrome (EX1004)	84
	2. The Differences Between the Claims and Prior Art	84
	a) Claims 1 and 4	84
	b) Dependent Claims	90
Ι	D. Ground 4: Claims 8-14 and 16 Would Have Been Obviou	us Over Citrome,
	the Paliperidone Formulary and the '544 Patent	91
	3. The Scope and Content of the Prior Art	91
	a) The '544 Patent (EX1005)	91
	b) Citrome (EX1004)	92
	c) Paliperidone Formulary (EX1006)	92
	4. The Differences Between the Claims and Prior Art	92
	a) Claims 8 and 11	92
	b) Dependent Claims	98
Ω	SECONDARY CONSIDERATIONS	90



- I, Mansoor M. Amiji, Ph.D., R.Ph. do hereby declare and state as follows:
- 1. I have been asked to provide testimony as to what one of ordinary skill in the art would have understood with respect to the patent at issue and various prior art discussed herein. I provide this testimony below:

1. INTRODUCTION

- 2. I am over the age of eighteen (18) and otherwise competent to make this declaration.
- 3. I have been retained as an expert witness on behalf of Petitioner Mylan Laboratories Ltd. for the above captioned *inter partes* review ("IPR"). I am being compensated for my time in connection with this IPR at my standard consulting rate, which is \$750.00 per hour. My compensation is in no way dependent on the outcome of this IPR.
- 4. I understand that the petition for IPR involves U.S. Patent No. 9,439,906 ("the '906 patent") (EX1001).
- 5. The '906 patent names An Vermeulen and Alfons Wouters as the purported inventors.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

